Company will also display E.Cam from SiemensAt its Society of Nuclear Medicine booth, Toshiba America Medical Systems, of Tustin, CA, plans to highlight the processing speed of the latest version of its nuclear medicine workstation. Toshiba's
Company will also display E.Cam from Siemens
At its Society of Nuclear Medicine booth, Toshiba America Medical Systems, of Tustin, CA, plans to highlight the processing speed of the latest version of its nuclear medicine workstation. Toshiba's computer is running on an Ultra 1 170, which is based on a speedy UltraSPARC CPU developed by Sun Microsystems of Mountain View, CA.
Toshiba decided to switch to the Sun platform in 1992 and follow the computer developer as it brings faster new workstations to market, according to Steve Sickels, acting director of Toshiba's nuclear medicine business unit. Since then, Toshiba has developed its software to make the transfer to each new Sun platform as seamless as possible.
"It's nice to take software off an old Sun computer, put it on a brand-new one, and see it work three or four times faster," Sickels said. "We don't have to wait a long time to reconfigure and reprogram software to make it run on new Sun systems."
Toshiba has made its workstation technology a major point of differentiation between itself and its nuclear medicine competitors. That's readily apparent in the recent agreement Toshiba signed with Siemens to sell that vendor's E.Cam variable-angle dual-head gamma camera (SCAN 4/2/97). Toshiba's version of E.Cam will be sold with Toshiba's Ultra workstation, rather than the Icon computer developed by Siemens.
Toshiba will display an E.Cam gantry in its SNM booth, in addition to other cameras in the company line, like the fixed-angle dual-head GCA 7200A and single-head GCA 7100A, both of which also employ Ultra computers. Toshiba is ready to begin taking orders for E.Cams, and plans to begin shipping them in the fourth quarter. E.Cam enables Toshiba to participate in the cardiac imaging segment of nuclear medicine for the first time, and the company plans to discuss cardiac applications such as quantitative gated SPECT, according to Sickels.
In other areas of its booth, Toshiba will emphasize DICOM connectivity and the ability to use the Internet to transfer images with Toshiba's Infinia personal computer. Another Toshiba technology, digital video disk (DVD) will be displayed as a possible high-density storage medium for nuclear medicine images. Toshiba is still 12 to 18 months away from selling DVD to the clinical market, as the company is still working on rewritable DVD technology, Sickels said.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.